Clinical benefit of metaphase I oocytesReportar como inadecuado

Clinical benefit of metaphase I oocytes - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Reproductive Biology and Endocrinology

, 3:71

First Online: 15 December 2005Received: 20 October 2005Accepted: 15 December 2005


BackgroundWe studied the benefit of using in vitro matured metaphase I MI oocytes for ICSI in patients with a maximum of 6 mature metaphase II MII oocytes at retrieval.

MethodsIn 2004, 187 ICSI cycles were selected in which maximum 6 MII oocytes and at least one MI oocyte were retrieved. MI oocytes were put in culture to mature until the moment of ICSI, which was performed between 2 to 11 hours after oocyte retrieval day 0. In exceptional cases, when the patient did not have any mature oocyte at the scheduled time of ICSI, MI oocytes were left to mature overnight and were injected between 19 to 26 hours after retrieval day 1. Embryos from MI oocytes were chosen for transfer only when no other good quality embryos from MII oocytes were available. Outcome parameters were time period of in vitro maturation IVM, IVM and fertilization rates, embryo development, clinical pregnancy rates, implantation rates and total MI oocyte utilization rate.

ResultsThe overall IVM rate was 43%. IVM oocytes had lower fertilization rates compared to in vivo matured sibling oocytes 52% versus 68%, P < 0.05. The proportion of poor quality embryos was significantly higher in IVM derived oocytes. One pregnancy and live birth was obtained out of 13 transfers of embryos exclusively derived from IVM oocytes. This baby originated from an oocyte that was injected after 22 hrs of IVM.

ConclusionFertilization of in vitro matured MI oocytes can result in normal embryos and pregnancy, making IVM worthwhile, particularly when few MII oocytes are obtained at retrieval.

Download fulltext PDF

Autor: Leen Vanhoutte - Petra De Sutter - Josiane Van der Elst - Marc Dhont


Documentos relacionados